Electromed, Inc. (ELMD)

Over the past six months, Electromed, Inc. announced a share repurchase authorization in September 2025. In November 2025, the company reported a 15.1% increase in net revenues and a 44.9% rise in net income for the First Quarter Fiscal 2026. In December 2025, Electromed reported record financial performance for its Second Quarter Fiscal 2026, with significant increases in net revenues, operating income, and net income, and repurchased $2.8 million in common stock. In February 2026, Electromed achieved its 13th consecutive quarter of year-over-year revenue and profit growth, benefited from increased market awareness due to the launch of Brensupri, and executed 25 new payer contracts. Despite strong financial growth, the company's stock price experienced volatility, falling below $25 by February 2026 after reaching an all-time high of $34.

Information regarding specific demand seasonality for Electromed, Inc.'s products and services is available through seasonality analysis tools, but the detailed patterns require access to premium features or a registered account on financial data platforms.

Electromed, Inc. specializes in airway clearance therapy, operating in the Healthcare sector, specifically in Healthcare Equipment & Supplies and Advanced Medical Equipment & Technology. The company's core business revolves around High Frequency Chest Wall Oscillation (HFCWO) technologies, with its major product being the SmartVest Airway Clearance System, prescribed for conditions such as bronchiectasis, cystic fibrosis, and neuromuscular conditions. Electromed also offers the SmartVest SQL System, SmartVest Clearway System, SmartVest Connect, and Single Patient Use (SPU) SmartVest and SmartVest Wrap products.

Electromed, Inc. markets its products to physicians, healthcare providers, and directly to patients in the United States and internationally. The company's direct homecare business is a core market, complemented by sales through hospital and homecare distributor channels.

Electromed, Inc. has maintained a positive brand reputation as a leader in airway clearance technologies, recognized for the efficacy and patient adherence of its products. Consistent revenue growth and margin improvement contribute to a favorable perception of its business performance. The introduction of Brensupri has been viewed as complementary to Electromed's SmartVest system, potentially enhancing the company's standing in the market. However, some analysis suggests that Electromed may lack a "durable moat" compared to rivals, and questions have been raised regarding the comparative efficacy of HFCWO versus alternative airway clearance therapies.

Electromed, Inc.'s ownership structure includes a mix of institutional, retail, and individual investors. Approximately 15.73% to 35.43% of the company's stock is held by institutional investors, 7.21% by insiders, and 9.39% to 57.35% by public companies and individual investors. Major institutional holders include The Vanguard Group, Inc., BlackRock, Inc., and others.